Amneal Pharmaceuticals Reprices Term Loan, Securing $11M in Annual Interest Savings

summarizeSummary

Amneal Pharmaceuticals amended its term loan credit agreement, reducing interest rate margins by 50 basis points, which is projected to save the company $11 million annually in cash interest expenses.

check_boxKey Events

• Term Loan Repricing

  Amneal Pharmaceuticals LLC, a subsidiary, entered into Amendment No. 2 to its Term Loan Credit Agreement, dated February 2, 2026. This repricing converted existing term loans into new term loans totaling approximately $1.96 billion and incurred an additional new term loan of approximately $134.7 million.

• Interest Rate Reduction

  The amendment reduces the applicable interest rate margin on the new term loans by 50 basis points (0.50%), setting it at 2.00% for base rate loans and 3.00% for secured overnight financing rate (SOFR) loans.

• Annualized Cash Interest Savings

  The company estimates that this repricing will result in approximately $11 million in annualized cash interest expense savings compared to the previous credit agreement.

• Maturity Date Unchanged

  The maturity date of the term loans, August 1, 2032, remains unchanged by this amendment.

auto_awesomeAnalysis

Amneal Pharmaceuticals has successfully repriced its existing term loan, reducing the interest rate margin by 50 basis points. This proactive financial management move is expected to generate approximately $11 million in annualized cash interest expense savings. The transaction converts existing term loans and incurs a new term loan, maintaining the original maturity date. This positive development enhances the company's financial flexibility and cash flow, building on recent positive news regarding its opioid settlement and strong financial guidance, and comes as the stock trades near its 52-week high.